Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Follow-Up Questions
Ginkgo Bioworks Holdings Inc 'in CEO'su kimdir?
Dr. Jason Kelly 2021 'den beri şirketle birlikte olan Ginkgo Bioworks Holdings Inc 'in Chief Executive Officer 'ıdır.
DNA hissesinin fiyat performansı nasıl?
DNA 'in mevcut fiyatı $11.54 'dir, son işlem günde 0.4% decreased etti.
Ginkgo Bioworks Holdings Inc için ana iş temaları veya sektörler nelerdir?
Ginkgo Bioworks Holdings Inc Life Sciences Tools & Services endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 4 analist Ginkgo Bioworks Holdings Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 0 güçlü al, 1 al, 2 tut, 5 sat ve 0 güçlü sat içermektedir
